Retevmo — Competitive Intelligence Brief

Retevmo (SELPERCATINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret Oncology Small molecule

Target snapshot

Retevmo (SELPERCATINIB) — Eli Lilly. Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Retevmo TARGET	SELPERCATINIB	Eli Lilly	marketed	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2020-01-01
Lenvima	LENVATINIB	Eisai	marketed	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2015-01-01
Amitriptyline Oxide	AMITRIPTYLINOXIDE		phase 3		Proto-oncogene tyrosine-protein kinase receptor Ret
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01

Recent regulatory actions (last 90 days)

• 2026-02-26 — Hernexeos · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor [EPC] class)

1. · 12 drugs in this class
2. Pfizer · 7 drugs in this class
3. Novartis · 3 drugs in this class
4. Bayer · 2 drugs in this class
5. Boehringer Ingelheim · 2 drugs in this class
6. AstraZeneca · 2 drugs in this class
7. Beigene Usa Inc · 1 drug in this class
8. BeiGene · 1 drug in this class
9. AbbVie · 1 drug in this class
10. Bristol · 1 drug in this class